株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaPoint:非小細胞肺がん - 世界の医薬品の予測と市場分析

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

発行 GlobalData 商品コード 307125
出版日 ページ情報 英文 390 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
PharmaPoint:非小細胞肺がん - 世界の医薬品の予測と市場分析 PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
出版日: 2014年04月30日 ページ情報: 英文 390 Pages
概要

非小細胞肺がん(NSCLC)は最も一般的な肺がんで、男女を問わず二番目に患者数のおおい癌でもあります。かつて、治療パラダイムは化学療法のみでしたが、特殊なバイオマーカーを有する患者向けの標的療法が登場して以来、市場は各々の患者に対応して、より細かく分類されるようになりました。今後もこの傾向は続き、様々な患者のアンメットニーズに対応した新薬が開発・上市され、これまで治療不可能だった患者にも対応できるようになると期待されます。

当レポートでは、全世界の非小細胞肺がん(NSCLC)市場の現状と将来展望について分析し、疾患の概要や今後の疫学的予測、主要国での予防体性、主要企業のプロファイルと代表的製品、市場のアンメットニーズと将来的な機会、現在治験中のパイプライン製品の情報、今後の市場規模と影響要因などを調査しております。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態
    • 病因
    • 病態生理・病歴
    • NSCLCのバイオマーカー
    • 生活の質(QoL)
  • 症状

第4章 疫学

  • リスク要因と共存症
    • 喫煙者は非喫煙者よりも肺がんリスクが高い
    • ラドンへの長期的被爆は肺がんリスクを高める
    • 各種がんの家族歴は肺がんリスクを高める
    • 結核(TB)は肺がんリスク・死亡率を高める
    • 慢性閉塞性肺疾患(COPD):肺がんの生存率を下げる共存症
    • 肺がん検査プログラムはあまり有効的でない
    • 各ステージでの診断が肺がんの生存率を大幅に高める
  • 世界各地での傾向
    • 米国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • 英国
    • 日本
    • 中国
    • インド
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法
  • 疫学的予測(今後11年間分)
    • NSCLCの発症件数・有病者数(総数)
    • NSCLCの発症件数(年齢別)
    • NSCLCの発症件数(男女別)
    • NSCLCの年齢調整済み発症件数
    • NSCLC患者の分類
  • 議論
    • 世界各国のワクチン摂取率の見通し
    • 分析の限界
    • 分析の強み

第5章 疾患の管理

  • 治療の概要
    • 診断
    • 臨床病期
    • 検査・早期発見
    • 局所的処置・治療法
    • 全身への化学療法
    • 標的療法
  • 米国
    • 診断
    • 臨床診療
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • 中国
  • インド

第6章 競争環境

  • 概要
  • 競合企業の戦略的評価
  • 製品プロファイル:主要ブランド−−化学療法
    • Alimta (ペメトレキセド・二ナトリウム)
    • Abraxane (nab-パクリタキセル)
  • 製品プロファイル:主要ブランド−−標的療法
    • アバスチン(ベバシズマブ)
    • Gilotrif(アファチニブ)
    • Iressa (ゲフィチニブ)
    • Tarceva (塩酸エルロチニブ)
    • Xalkori (クリゾチニブ)

第7章 市場機会とアンメットニーズ

  • 概要
  • 全体的な生存率の改善と毒性の軽減
  • チロシンキナーゼ阻害薬(TKI)の後天的耐性のある患者への治療法
  • 扁平上皮細胞がん患者へのより良い治療オプション
  • 退行・再発防止
  • より効果的な第二選択療法
  • 変異性解析の利用可能性の改善
  • よりコスト効率的な治療法
  • アンメットニーズ・ギャップの分析

第8章 パイプライン評価

  • 概要
  • 治験マッピング(国別)
  • 相別・治験段階別の治験進行状況
  • 治験中の有望な医薬品
    • Onartuzumab (MetMab)
    • Necitumumab (IMC-11F8)
    • Ramucirumab (IMC-1121B)
    • Custirsen (OGX-011)
    • Ganetespib (STA-9090)
    • Nintedanib (BIBF1120)
    • Dacomitinib (PF-00299804)
    • LDK378 (ceritinib)
    • Yervoy (ipilimumab)
    • Nivolumab (BMS936558)
    • MPDL3280A (RG7446)
    • GSK1572932A (MAGE-A3がん免疫療法)
    • Halaven (メシル酸エリブリン)

第9章 現在・将来の市場参入企業

  • 概要
  • 企業戦略の概要
  • 企業プロファイル
    • Roche/Genentech
    • Pfizer
    • Bristol-Myers Squibb
    • Eli Lilly
    • Boehringer Ingelheim
    • Novartis

第10章 市場の見通し

  • 世界市場
    • 市場予測
    • 市場促進・阻害要因:世界的課題
  • 米国
    • 市場予測
    • 近年の主な出来事
    • 市場促進・阻害要因
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • 中国
  • インド

第11章 付録

図表一覧

目次
Product Code: GDHC002EPIDR

Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations.

This Event-Driven Update was published in response to major events that occurred during the first quarter of 2014 that will result in the failure of several premium-priced agents to launch in the US and global markets during the forecast period. These agents include Pfizer's dacomitinib and Boehringer Ingelheim's nintedanib in the US, and Roche's MetMab (onartuzumab) and GSK's MAGE-A3 immunotherapy in the global markets.

Highlights

Key Questions Answered

  • The NSCLC market will become increasingly crowded during the forecast. How will the first and second lines of therapy be impacted by the launch of new therapies?
  • How will the failure of dacomitinib and nintedanib to launch in the US affect global market growth? What effect will the failure to launch of MetMab (onartuzumab) and the MAGE-A3 immunotherapy in the nine major markets have on global market dynamics?
  • How will the increasing stratification of patient populations by biomarkers affect the treatment landscape?
  • The unmet needs of NSCLC patients are relatively high. What unmet needs will be addressed by the launch of new treatment options during the forecast period? What unmet needs will remain?
  • How will Alimta, Avastin, Iressa and Tarceva patent expirations affect overall market growth during the forecast?
  • How will increasing cost consciousness among European reimbursement authorities affect market growth in the 5EU?

Key Findings

  • Launch of emerging pipeline therapies will result in more patients receiving premium-priced drugs in the first and second lines of therapy, and market growth in the US and Japan. However, the US and nine major markets will be negatively affected by the failure of premium-priced agents including dacomitinib, nintedanib, MetMab and MAGE-A3 to launch during the forecast period.
  • Despite the launch of remaining premium-priced therapies such as Eli Lilly's necitumumab and BMS' nivolumab, the NSCLC market will shrink in the 5EU. This will be primarily due to the reduction in number of new premium-priced agents that will launch as well as the loss of patent protection for most of the major branded therapies as well as increasing cost pressures from European reimbursement authorities.
  • The Indian and Chinese markets will continue to be difficult to penetrate. Many emerging pipeline therapies will not launch in these markets, especially expensive biologic therapies. Generic competition, regulatory hurdles and high cost of therapies will be major barriers to growth in these markets.
  • BMS's nivolumab will emerge as the overall market leader in 2022, launching first in the second-line segment in 2015 and expanding into the first-line segment in 2019. Uptake will be driven by the drug's promising clinical efficacy in both squamous and non-squamous patients and strong safety profile.
  • After Iressa and Tarceva lose patent protection in 2019 and 2020, respectively, Boehriger Ingelheim's Gilotrif (afatinib) will emerge as the leading therapy for EGFR-positive patients. Gilotrif's market position will be driven by high uptake in the second-line segment.
  • Pfizer's Xalkori will lose ALK-positive patient share to Novartis' ceritinib (LDK378) in the second-line segment. However, Xalkori will continue to be the patient share leader in the more lucrative first line setting and will maintain the overall sales leadership over LDK378 throughout the forecast.

Scope

  • Overview of NSCLC, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized NSCLC therapeutics market revenue, annual cost of therapy and treatment usage pattern data by patient segment forecast from 2012 to 2022.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the NSCLC therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising 13 candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global NSCLC market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global NSCLC therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global NSCLC therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Forecast drug sales in the global NSCLC therapeutics market from 2012-2022.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology and Histology
    • 3.1.3. NSCLC Biomarkers
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Epidemiology

  • 4.1. Risk Factors and Comorbidities
    • 4.1.1. Smokers are more likely to have lung cancer than non-smokers
    • 4.1.2. Long-term exposure to radon increases the risk of lung cancer
    • 4.1.3. Family history of any cancer increases lung cancer risk
    • 4.1.4. TB increases the risk of lung cancer and increases mortality risk
    • 4.1.5. COPD is a comorbidity that reduces lung cancer survival
    • 4.1.6. Lung cancer screening programs may not be beneficial
    • 4.1.7. Stage at diagnosis significantly impacts the survival of lung cancer cases
  • 4.2. Global Trends
    • 4.2.1. US
    • 4.2.2. France
    • 4.2.3. Germany
    • 4.2.4. Italy
    • 4.2.5. Spain
    • 4.2.6. UK
    • 4.2.7. Japan
    • 4.2.8. China
    • 4.2.9. India
  • 4.3. Forecast Methodology
    • 4.3.1. Sources Used
    • 4.3.2. Sources Not Used
    • 4.3.3. Forecast Assumptions and Methods
  • 4.4. Epidemiology Forecast (2012-2022)
    • 4.4.1. Incident/Prevalent Cases of NSCLC
    • 4.4.2. Age-Specific Incident Cases of NSCLC
    • 4.4.3. Sex-Specific Incident Cases of NSCLC
    • 4.4.4. Age-Standardized Incidence Rates of NSCLC
    • 4.4.5. Segmentation of NSCLC Incident Cases
  • 4.5. Discussion
    • 4.5.1. Limitations of the Analysis
    • 4.5.2. Strengths of the Analysis

5. Disease Management

  • 5.1. Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Clinical Staging
    • 5.1.3. Screening and Early Detection
    • 5.1.4. Localized Procedures and Therapies
    • 5.1.5. Systemic Chemotherapy
    • 5.1.6. Targeted Therapy
  • 5.2. US
    • 5.2.1. Diagnosis
    • 5.2.2. Clinical Practice
  • 5.3. France
    • 5.3.1. Diagnosis
    • 5.3.2. Clinical Practice
  • 5.4. Germany
    • 5.4.1. Diagnosis
    • 5.4.2. Clinical Practice
  • 5.5. Italy
    • 5.5.1. Diagnosis
    • 5.5.2. Clinical Practice
  • 5.6. Spain
    • 5.6.1. Diagnosis
    • 5.6.2. Clinical Practice
  • 5.7. UK
    • 5.7.1. Diagnosis
    • 5.7.2. Clinical Practice
  • 5.8. Japan
    • 5.8.1. Diagnosis
    • 5.8.2. Clinical Practice
  • 5.9. China
    • 5.9.1. Diagnosis
    • 5.9.2. Clinical Practice
  • 5.10. India
    • 5.10.1. Diagnosis
    • 5.10.2. Clinical Practice

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Strategic Competitor Assessment
  • 6.3. Product Profiles - Major Brands, Chemotherapies
    • 6.3.1. Alimta (pemetrexed disodium)
    • 6.3.2. Abraxane (nab-paclitaxel)
  • 6.4. Product Profiles - Major Brands, Targeted Therapies
    • 6.4.1. Avastin (bevacizumab)
    • 6.4.2. Gilotrif (afatinib)
    • 6.4.3. Iressa (gefitinib)
    • 6.4.4. Tarceva (erlotinib hydrochloride)
    • 6.4.5. Xalkori (crizotinib)

7. Opportunity and Unmet Need

  • 7.1. Overview
  • 7.2. Improved Overall Survival and Less Toxicity
  • 7.3. Treatments for Patients with Acquired TKI Resistance
  • 7.4. Better Treatment Options for Squamous Patients
  • 7.5. Preventing Relapse or Recurrence
  • 7.6. More Efficacious Second-Line Therapies
  • 7.7. Increased Availability of Mutation Testing
  • 7.8. More Cost-Effective Therapies
  • 7.9. Unmet Needs Gap Analysis

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Country
  • 8.3. Clinical Trials by Phase and Trial Status
  • 8.4. Promising Drugs in Clinical Development
    • 8.4.1. Onartuzumab (MetMab)
    • 8.4.2. Necitumumab (IMC-11F8)
    • 8.4.3. Ramucirumab (IMC-1121B)
    • 8.4.4. Custirsen (OGX-011)
    • 8.4.5. Ganetespib (STA-9090)
    • 8.4.6. Nintedanib (BIBF1120)
    • 8.4.7. Dacomitinib (PF-00299804)
    • 8.4.8. LDK378. (ceritinib)
    • 8.4.9. Yervoy (ipilimumab)
    • 8.4.10. Nivolumab (BMS936558)
    • 8.4.11. MPDL3280A (RG7446)
    • 8.4.12. GSK1572932A (MAGE-A3. Cancer Immunotherapy)
    • 8.4.13. Halaven (eribulin mesylate)

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Roche/Genentech
    • 9.3.2. Pfizer
    • 9.3.3. Bristol-Myers Squibb
    • 9.3.4. Eli Lilly
    • 9.3.5. Boehringer Ingelheim
    • 9.3.6. Novartis

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. United Kingdom
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers
  • 10.9. China
    • 10.9.1. Forecast
    • 10.9.2. Key Events
    • 10.9.3. Drivers and Barriers
  • 10.10. India
    • 10.10.1. Forecast
    • 10.10.2. Key Events
    • 10.10.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Number of NSCLC Patients Currently Seeking Treatment
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Physicians and Specialists Included in This Study
  • 11.6. Survey of Prescribing Physicians
  • 11.7. About the Authors
    • 11.7.1. Authors
    • 11.7.2. Epidemiologists
    • 11.7.3. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Symptoms of NSCLC
  • Table 2: Risk Factors and Comorbidities for Lung Cancer
  • Table 3: 9MM, Age-Standardized (World) Smoking Prevalence, Men and Women, 2006 and 2009
  • Table 4: 9MM, Sources of NSCLC Incidence Data
  • Table 5: 9MM, Incident Cases of NSCLC, Men and Women Ages ≥40 Years, N, Selected Years 2012-2022
  • Table 6: 9MM, Incident Cases of NSCLC, by Age, Men and Women, N (Row %), 2012
  • Table 7: 9MM, Incident Cases of NSCLC, by Sex, Ages ≥40 Years, N (Row %), 2012
  • Table 8: 9MM, Incident Cases of NSCLC, by Stage at Diagnosis, Men and Women Ages ≥40 Years, N (Row %), 2012
  • Table 9: 9MM, Incident Cases of NSCLC, by Histological Subtype, Ages ≥40 Years, Men and Women, N (Row %) , 2012
  • Table 10: Comparison of GlobalData Forecast for Lung Cancer Incident Cases With Globocan 2008
  • Table 11: Treatment Guidelines for NSCLC
  • Table 12: Stage Definitions for NSCLC
  • Table 13: Treatment Overview by Stage of Diagnosis for NSCLC
  • Table 14: Leading Branded Treatments for NSCLC
  • Table 15: Product Profile - Alimta (pemetrexed disodium)
  • Table 16: Alimta SWOT Analysis, 2013
  • Table 17: Global Sales Forecasts ($m) for Alimta, 2012-2022
  • Table 18: Product Profile - Abraxane (nab-paclitaxel)
  • Table 19: Abraxane SWOT Analysis, 2013
  • Table 20: Global Sales Forecasts ($m) for Abraxane, 2012-2022
  • Table 21: Product Profile - Avastin (bevacizumab)
  • Table 22: Avastin SWOT Analysis, 2013
  • Table 23: Global Sales Forecasts ($m) for Avastin, 2012-2022
  • Table 24: Product Profile - Gilotrif (afatinib)
  • Table 25: Gilotrif SWOT Analysis, 2013
  • Table 26: Global Sales Forecasts ($m) for Gilotrif, 2012-2022
  • Table 27: Product Profile - Iressa (gefitinib)
  • Table 28: Iressa SWOT Analysis, 2013
  • Table 29: Global Sales Forecasts ($m) for Iressa, 2012-2022
  • Table 30: Product Profile - Tarceva (erlotinib hydrochloride)
  • Table 31: Tarceva SWOT Analysis, 2013
  • Table 32: Global Sales Forecasts ($m) for Tarceva, 2012-2022
  • Table 33: Product Profile - Xalkori (crizotinib)
  • Table 34: Xalkori SWOT Analysis, 2013
  • Table 35: Global Sales Forecasts ($m) for Xalkori, 2012-2022
  • Table 36: Overall Unmet Needs - Current Level of Attainment
  • Table 37: Clinical Unmet Needs - Gap Analysis, 2013
  • Table 38: NSCLC - Clinical Trials by Phase and Status, 2013
  • Table 39: NSCLC - Promising Candidates in the Phase I-II Pipeline, 2013
  • Table 40: NSCLC - Phase III Pipeline, 2013
  • Table 41: NSCLC - Advantages and Disadvantages of Therapeutic Drug Classes
  • Table 42: Product Profile - Onartuzumab (MetMab)
  • Table 43: Product Profile - Necitumumab (IMC-11F8)
  • Table 44: Necitumumab SWOT Analysis, 2013
  • Table 45: Global Sales Forecasts ($m) for Necitumumab, 2012-2022
  • Table 46: Product Profile - Ramucirumab (IMC-1121B)
  • Table 47: Ramucirumab SWOT Analysis, 2013
  • Table 48: Global Sales Forecasts ($m) for Ramucirumab, 2012-2022
  • Table 49: Product Profile - Custirsen (OGX-011)
  • Table 50: Custirsen SWOT Analysis, 2013
  • Table 51: Global Sales Forecasts ($m) for Custirsen, 2012-2022
  • Table 52: Product Profile - Ganetespib (STA-9090)
  • Table 53: Ganetespib SWOT Analysis, 2013
  • Table 54: Global Sales Forecasts ($m) for Ganetespib, 2012-2022
  • Table 55: Product Profile - Nintedanib (BIBF-1120)
  • Table 56: Nintedanib SWOT Analysis, 2013
  • Table 57: Global Sales Forecasts ($m) for Nintedanib, 2012-2022
  • Table 58: Product Profile - Dacomitinib (PF-00299804)
  • Table 59: Dacomitinib SWOT Analysis, 2013
  • Table 60: Global Sales Forecasts ($m) for Dacomitinib, 2012-2022
  • Table 61: Product Profile - LDK378
  • Table 62: LDK378 SWOT Analysis, 2013
  • Table 63: Global Sales Forecasts ($m) for LDK378, 2012-2022
  • Table 64: Product Profile - Yervoy (ipilimumab)
  • Table 65: Yervoy SWOT Analysis, 2013
  • Table 66: Global Sales Forecasts ($m) for Yervoy, 2012-2022
  • Table 67: Product Profile - Nivolumab (BMS936558)
  • Table 68: Nivolumab SWOT Analysis, 2013
  • Table 69: Global Sales Forecasts ($) for Nivolumab, 2012-2022
  • Table 70: Product Profile - MPDL3280A (RG7446)
  • Table 71: MPDL3280A SWOT Analysis, 2013
  • Table 72: Product Profile - GSK1572932A (MAGE-A3 Immunotherapy)
  • Table 73: Product Profile - Halaven (eribulin mesylate)
  • Table 74: Halaven SWOT Analysis, 2013
  • Table 75: Global Sales Forecasts ($m) for Halaven, 2012-2022
  • Table 76: Key Companies in the NSCLC Market, 2013
  • Table 77: Roche/Genentech's NSCLC Portfolio Assessment, 2013
  • Table 78: Roche/Genentech SWOT Analysis, 2013
  • Table 79: Pfizer's NSCLC Portfolio Assessment, 2013
  • Table 80: Pfizer SWOT Analysis, 2013
  • Table 81: BMS' NSCLC Portfolio Assessment, 2013
  • Table 82: BMS SWOT Analysis, 2013
  • Table 83: Eli Lilly's NSCLC Portfolio Assessment, 2013
  • Table 84: Eli Lilly SWOT Analysis, 2013
  • Table 85: BI's NSCLC Portfolio Assessment, 2013
  • Table 86: BI SWOT Analysis, 2013
  • Table 87: Novartis NSCLC Portfolio Assessment, 2013
  • Table 88: Novartis SWOT Analysis, 2013
  • Table 89: Global Sales Forecasts ($m) for NSCLC, 2012-2022
  • Table 90: Global NSCLC Market - Drivers and Barriers, 2012-2022
  • Table 91: Sales Forecasts ($m) for NSCLC in the United States, 2012-2022
  • Table 92: Key Events Impacting Sales for NSCLC in the United States, 2012-2022
  • Table 93: NSCLC Market in the United States - Drivers and Barriers, 2012-2022
  • Table 94: Sales Forecasts ($m) for NSCLC in France, 2012-2022
  • Table 95: Key Events Impacting Sales for NSCLC in France, 2012-2022
  • Table 96: NSCLC Market in France - Drivers and Barriers, 2012-2022
  • Table 97: Sales Forecasts ($m) for NSCLC in Germany, 2012-2022
  • Table 98: Key Events Impacting Sales for NSCLC in Germany, 2012-2022
  • Table 99: NSCLC Market in Germany - Drivers and Barriers, 2012-2022
  • Table 100: Sales Forecasts ($m) for NSCLC in Italy, 2012-2022
  • Table 101: Key Events Impacting Sales for NSCLC in Italy, 2012-2022
  • Table 102: NSCLC Market in Italy - Drivers and Barriers, 2012-2022
  • Table 103: Sales Forecasts ($m) for NSCLC in Spain, 2012-2022
  • Table 104: Key Events Impacting Sales for NSCLC in Spain, 2012-2022
  • Table 105: NSCLC Market in Spain - Drivers and Barriers, 2012-2022
  • Table 106: Sales Forecasts ($m) for NSCLC in the UK, 2012-2022
  • Table 107: Key Events Impacting Sales for NSCLC in the UK, 2012-2022
  • Table 108: NSCLC Market in the United Kingdom - Drivers and Barriers, 2012-2022
  • Table 109: Sales Forecasts ($m) for NSCLC in Japan, 2012-2022
  • Table 110: Key Events Impacting Sales for NSCLC in Japan, 2012-2022
  • Table 111: NSCLC Market in Japan - Drivers and Barriers, 2012-2022
  • Table 112: Sales Forecasts ($m) for NSCLC in China, 2012-2022
  • Table 113: Key Events Impacting Sales for NSCLC in China, 2012-2022
  • Table 114: NSCLC Market in China - Drivers and Barriers, 2012-2022
  • Table 115: Sales Forecasts ($m) for NSCLC in India, 2012-2022
  • Table 116: Key Events Impacting Sales for NSCLC in India, 2012-2022
  • Table 117: NSCLC Market in India - Drivers and Barriers, 2012-2022
  • Table 118: Five-Year Prevalence of NSCLC
  • Table 119: Key Launch Dates
  • Table 120: Key Patent Expiries
  • Table 121: Physicians Surveyed by Country

List of Figures

  • Figure 1: 9MM, Age-Standardized (World) Lung Cancer Incidence, Men Ages ≥40 Years, 1993-2002
  • Figure 2: 9MM, Age-Standardized (World) Lung Cancer Incidence, Women Ages ≥40 Years, 1993-2002
  • Figure 3: Age-Standardized (US, 2000) Lung Cancer Incidence and Mortality, Men and Women, All Ages, US, 1999-2008
  • Figure 4: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ≥40 Years, US, 1993-2008
  • Figure 5: Relative Risk of Death from Lung Cancer in Current Smokers, Men and Women, US
  • Figure 6: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ≥40 Years, France, 1993-2008
  • Figure 7: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ≥40 Years, Germany, 1993-2008
  • Figure 8: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ≥40 Years, Italy, 1993-2008
  • Figure 9: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ≥40 Years, Spain, 1991-2008
  • Figure 10: Age-Standardized (World) Lung Cancer Incidence and Mortality, Ages ≥40 Years, UK, 1993-2008
  • Figure 11: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ≥40 Years, Japan, 1993-2008
  • Figure 12: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ≥40 Years, China, 1993-2008
  • Figure 13: Age-Standardized (World) Lung Cancer Incidence, Men and Women Ages ≥40 Years, India, 1993-2002
  • Figure 14: 9MM, Incident Cases of NSCLC, Men and Women Ages ≥40 Years, N, Selected Years 2012-2022
  • Figure 15: 9MM, Incident Cases of NSCLC, by Sex, Ages ≥40 Years, N, 2012
  • Figure 16: 9MM, Age-Standardized (World) NSCLC Incidence, 2012
  • Figure 17: 9MM, Incident Cases of NSCLC, by Stage at Diagnosis, Men and Women Ages ≥40 Years, % and N, 2012
  • Figure 18: 9MM, Incident Cases of NSCLC by Histological Subtype, Men and Women Ages ≥40 Years, %, 2012
  • Figure 19: 9MM, Proportion of Smokers Among NSCLC Cases Ages >40 Years and the General Population, Men and Women, %, 2012
  • Figure 20: Smoking History in NSCLC Cases in the 9MM, Men and Women Ages ≥40 Years, N, 2012
  • Figure 21: NSCLC Therapeutics - Clinical Trials by Country, 2013
  • Figure 22: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 2012-2022
  • Figure 23: Company Portfolio Gap Analysis in NSCLC, 2012-2022
  • Figure 24: Global Sales for NSCLC by Region, 2012-2022
  • Figure 25: Sales for NSCLC in the US by Drug Class, 2012-2022
  • Figure 26: Sales for NSCLC in France by Drug Class, 2012-2022
  • Figure 27: Sales for NSCLC in Germany by Drug Class, 2012-2022
  • Figure 28: Sales for NSCLC in Italy by Drug Class, 2012-2022
  • Figure 29: Sales for NSCLC in Spain by Drug Class, 2012-2022
  • Figure 30: Sales for NSCLC in the UK by Drug Class, 2012-2022
  • Figure 31: Sales for NSCLC in Japan by Drug Class, 2012-2022
  • Figure 32: Sales for NSCLC in China by Drug Class, 2012-2022
  • Figure 33: Sales for NSCLC in India by Drug Class, 2012-2022
Back to Top